Dartmouth College

Reata Pharmaceuticals, Inc.

University of California

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Rutgers, the State University of New Jersey

Osteoscreen, Inc.

Darmouth College

Gordon W Gribble

Michael B Sporn

Tadashi Honda

Karen T Liby

Nanjoo Suh

Liangfeng Fu

Evans O Onyango

Robert M Kral, Jr

Colin J Meyer

Ronald K Taylor

Martine Cao

Frank G Favaloro

Robert M Kral

Michael Sporn

F Jon Kull

Chitra Sundararajan

Anne R Kelley

Dmitry A Androsov

Justin M Lopchuk

Melean Visnick

Gregory R Mundy

Gary Delmar Jaycox

Pamela Gehron Robey

Alan Richard Eastman

A Hari Reddi

Takahiro Niikura

Ross Garrett

Dmity A Androsov

Nikolai V Moskalev

Damian Medici

Yukiko Honda

Michael Mosher

Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl) imidazole and pharmaceutical compositions containing the same are provided.

Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole

Bicyclic compounds for decreasing the expression of bacterial virulence factors thereby preventing, mitigating, or treating bacterial infection are provided.

Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection

Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl) imidazole and pharmaceutical compositions containing the same are provided. The present invention is a tnterpenoid compound of Formula I, or a hydrate, isomer, prodrug or pharmaceutically acceptable salt thereof: wherein one or more of R, R or R is independently a substituted or unsubstituted aryl group, heteroaryl group, cycloalkyl group or heterocyclyl group, and the remaining R groups are hydrogen. The pyridyl analogs of CD-DO-1m 1 have been developed, which are more stable in human plasma and achieve a higher concentration in target tissues such as liver, pancreas, kidney and lungs.

Compounds for inhibiting Type 4 Prepilin Peptidases are provided as are methods of using the compounds as anti-bacterial agents.

Type 4 prepilin peptidase inhibitors and methods of use

The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in combination with a second treatment or prophylaxis.

Synthetic triterpenoids and methods of use in the treatment of disease

The present invention provides triterpenoids produced from natural compounds such as oleanolic acid, ursolic acid, betulinic acid, and hederagenin.

Triterpenoids and compositions containing the same

2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid amino acid derivatives having antiinflammatory properties are provided. Pharmaceutical compositions and methods for preventing or treating inflammation or a disease or condition mediated by inflammation are described.

CDDO-Me amino acid conjugates and methods of use

Compounds and methods useful for chemopreventative treatment of diseases such as cancer, Alzheimer's disease, Parkinson's disease, inflammatory bowel diseases, and multiple sclerosis.

Therapeutic compounds and methods of use

Synthetic triterpenoids and methods of using the same to induce gene expression and differentiation of stem or progenitor cells are provided. Furthermore, the present invention provides methods for producing a cell, such as a stem or progenitor cell, with induced gene expression by contacting a stem or progenitor cell with an effective amount of a synthetic triterpenoid to induce the expression of one or more of SOX9 (Sex determining region Y-box 9), COL2A1 (Type II Collagen (alpha1)), TGF-&#x3b2;I, TGF-p2, TGF-33, BMP2, BMP4, BMPRII (Bone Morphogenic Protein Receptor II), SMAD (Small Mothers Against Decapentaplegic) 3, SMAD4, SMAD6, SMAD7, TIMP (Tissue Inhibitor of Metalloproteinase)-1 or TIMP-2 in the stem or progenitor cell, wherein the stem or progenitor cell is not a mesenchymal stem cell, periosteium cell or osteoprogenitor cell. In one embodiment, the stem or progenitor cell is multipotent.

Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression

The present invention is a method for preparing triterpenoids such as 2-cyano-3,12-dioxoolean-1,9-dien-28-methyl ester and derivatives thereof from oleanic acid, ursolic acid, betulinic acid, sumaresinolic acid or hederagenin.

Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof

The present invention is bis-acridine or bis-quinoline intercalators having a modified bis(4-aminophenyl)ether tether to improve activity, selectivity, solubility and bioavailability of the antitumor compound.

Compositions and methods for treating cancer

The present invention features the use of a synthetic triterpenoid to induce gene expression and differentiation of stem or progenitor cells in the treatment of bone/cartilage diseases or conditions.

Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions

Growing community of inventors

Lebanon, NH, United States of America

Gordon W Gribble